<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Spago Nanomedical Ab — News on 6ix</title>
<link>https://6ix.com/company/spago-nanomedical-ab</link>
<description>Latest news and press releases for Spago Nanomedical Ab on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 17 Mar 2026 11:10:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/spago-nanomedical-ab" rel="self" type="application/rss+xml" />
<item>
<title>Spago Nanomedical Continues Recruitment in The Phase I/IIa Tumorad-01 Study Following Positive DMC Recommendation</title>
<link>https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-continues-recruitment-in-the-phase-iiia-tumorad-01-study-following-positive-dmc-recommendation</link>
<guid isPermaLink="true">https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-continues-recruitment-in-the-phase-iiia-tumorad-01-study-following-positive-dmc-recommendation</guid>
<pubDate>Tue, 17 Mar 2026 11:10:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / March 17, 2026 / Spago Nanomedical AB (publ) (STO:SPAGO.ST)(FRA:7UX.F) announced today that the independent Data Monitoring Committee (DMC) recommends that the ongoing clinical phase I/IIa study Tumorad-01 with the drug ...</description>
</item>
<item>
<title>Spago Nanomedical Strengthens CMC and Supply Capabilities to Support Next Phase of Tumorad Development</title>
<link>https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-strengthens-cmc-and-supply-capabilities-to-support-next-phase-of-tumorad-development</link>
<guid isPermaLink="true">https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-strengthens-cmc-and-supply-capabilities-to-support-next-phase-of-tumorad-development</guid>
<pubDate>Tue, 10 Mar 2026 07:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / March 10, 2026 / Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) announced today that Torsten Malmström has assumed the position of Director CMC & Supply. Torsten Malmström also joins the company's Management Team, ...</description>
</item>
<item>
<title>Spago Nanomedical Year-End Report January-December, 2025</title>
<link>https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-end-report-january-072000579</link>
<guid isPermaLink="true">https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-end-report-january-072000579</guid>
<pubDate>Thu, 05 Feb 2026 07:20:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / February 5, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) OCTOBER - DECEMBER IN BRIEF Net sales for the quarter amounted to KSEK 4 (KSEK 617) The loss for the quarter amounted to KSEK -5,890 (KSEK -7,830) Operating ...</description>
</item>
<item>
<title>Nomination Committee Appointed for Spago Nanomedical's Annual General Meeting 2026</title>
<link>https://6ix.com/company/spago-nanomedical-ab/news/nomination-committee-appointed-for-spago-nanomedicals-annual-general-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/spago-nanomedical-ab/news/nomination-committee-appointed-for-spago-nanomedicals-annual-general-meeting-2026</guid>
<pubDate>Mon, 08 Dec 2025 10:00:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / December 8, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - In accordance with the instructions to the nomination committee resolved by the Annual General Meeting ("AGM"), a nomination committee for the 2026 AGM has ...</description>
</item>
<item>
<title>Spago Nanomedical Announces Outcome of Oversubscribed Rights Issue</title>
<link>https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-announces-outcome-of-oversubscribed-rights-issue</link>
<guid isPermaLink="true">https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-announces-outcome-of-oversubscribed-rights-issue</guid>
<pubDate>Mon, 24 Nov 2025 16:00:00 GMT</pubDate>
<description>NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION ...</description>
</item>
<item>
<title>The Subscription Period in Spago Nanomedical's Rights Issue Begins Today</title>
<link>https://6ix.com/company/spago-nanomedical-ab/news/the-subscription-period-in-spago-nanomedicals-rights-issue-begins-today</link>
<guid isPermaLink="true">https://6ix.com/company/spago-nanomedical-ab/news/the-subscription-period-in-spago-nanomedicals-rights-issue-begins-today</guid>
<pubDate>Fri, 07 Nov 2025 08:10:00 GMT</pubDate>
<description>NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION ...</description>
</item>
<item>
<title>Spago Nanomedical Resolves on a Rights Issue of Approximately SEK 25 million to Advance Tumorad</title>
<link>https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-resolves-on-a-rights-issue-of-approximately-sek-25-million-to-advance-tumorad</link>
<guid isPermaLink="true">https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-resolves-on-a-rights-issue-of-approximately-sek-25-million-to-advance-tumorad</guid>
<pubDate>Wed, 29 Oct 2025 08:00:00 GMT</pubDate>
<description>NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION ...</description>
</item>
<item>
<title>Spago Nanomedical Interim Report January-September 2025</title>
<link>https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-interim-report-january-september-2025</link>
<guid isPermaLink="true">https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-interim-report-january-september-2025</guid>
<pubDate>Wed, 29 Oct 2025 07:20:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / October 29, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) JULY - SEPTEMBER IN BRIEF Net sales for the quarter amounted to KSEK 14 (KSEK 485) The loss for the quarter amounted to KSEK -6,265 (KSEK -8,763) Operating ...</description>
</item>
<item>
<title>Visible Tumor Uptake and Recommended Dose Increase in Spago Nanomedicals's Phase I/IIa Study Tumorad-01</title>
<link>https://6ix.com/company/spago-nanomedical-ab/news/visible-tumor-uptake-and-recommended-dose-increase-in-spago-nanomedicalss-phase-iiia-study-tumorad-01</link>
<guid isPermaLink="true">https://6ix.com/company/spago-nanomedical-ab/news/visible-tumor-uptake-and-recommended-dose-increase-in-spago-nanomedicalss-phase-iiia-study-tumorad-01</guid>
<pubDate>Tue, 14 Oct 2025 09:50:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / October 14, 2025 / Spago Nanomedical AB (publ) (STO:SPAGO.ST)(FRA:7UX.F) announced today that the independent Data Monitoring Committee (DMC) recommends a dose increase in the ongoing Phase I/IIa clinical trial Tumorad-01 ...</description>
</item>
<item>
<title>Spago Nanomedical Interim Report January-June, 2025</title>
<link>https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-interim-report-january-june-2025</link>
<guid isPermaLink="true">https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-interim-report-january-june-2025</guid>
<pubDate>Wed, 20 Aug 2025 06:20:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / August 20, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) APRIL - JUNE IN BRIEF Net sales for the quarter amounted to KSEK 81 (KSEK 459) The loss for the quarter amounted to KSEK -6,964 (KSEK -8,152) Operating expenses ...</description>
</item>
<item>
<title>Spago Nanomedical Continues Patient Recruitment in the Phase I/IIa Study Tumorad-01 as Planned after DMC Recommendation</title>
<link>https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-continues-patient-recruitment-in-the-phase-iiia-study-tumorad-01-as-planned-after-dmc-recommendation</link>
<guid isPermaLink="true">https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-continues-patient-recruitment-in-the-phase-iiia-study-tumorad-01-as-planned-after-dmc-recommendation</guid>
<pubDate>Tue, 03 Jun 2025 06:20:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / June 3, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) announced today that the Data Monitoring Committee (DMC) recommends the ongoing phase I/IIa study Tumorad-01 with the candidate drug ...</description>
</item>
<item>
<title>Bulletin from the 2025 Annual General Meeting of Spago Nanomedical AB</title>
<link>https://6ix.com/company/spago-nanomedical-ab/news/bulletin-from-the-2025-annual-general-meeting-of-spago-nanomedical-ab</link>
<guid isPermaLink="true">https://6ix.com/company/spago-nanomedical-ab/news/bulletin-from-the-2025-annual-general-meeting-of-spago-nanomedical-ab</guid>
<pubDate>Wed, 14 May 2025 12:30:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / May 14, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, May 14, 2025, at which the AGM resolved to approve the income statement and balance ...</description>
</item>
<item>
<title>Spago Nanomedical Interim Report January-March, 2025</title>
<link>https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-interim-report-january-march-2025</link>
<guid isPermaLink="true">https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-interim-report-january-march-2025</guid>
<pubDate>Wed, 07 May 2025 06:20:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / May 7, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) OCTOBER - DECEMBER IN BRIEF Net sales for the quarter amounted to KSEK 338 (KSEK 350) The loss for the quarter amounted to KSEK -7,435 (KSEK -7,763) Operating ...</description>
</item>
<item>
<title>Notice To Annual General Meeting of Spago Nanomedical AB (PUBL)</title>
<link>https://6ix.com/company/spago-nanomedical-ab/news/notice-to-annual-general-meeting-of-spago-nanomedical-ab-publ</link>
<guid isPermaLink="true">https://6ix.com/company/spago-nanomedical-ab/news/notice-to-annual-general-meeting-of-spago-nanomedical-ab-publ</guid>
<pubDate>Wed, 09 Apr 2025 06:20:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / April 9, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) This English version of the notice to the Annual General Meeting is for convenience only. The Swedish version prevails in the event of any inconsistency. The ...</description>
</item>
<item>
<title>Nomination Committee's Proposal for a New Chairman and Composition of Spago Nanomedical’s Board</title>
<link>https://6ix.com/company/spago-nanomedical-ab/news/nomination-committees-proposal-for-a-new-chairman-and-composition-of-spago-nanomedicals-board</link>
<guid isPermaLink="true">https://6ix.com/company/spago-nanomedical-ab/news/nomination-committees-proposal-for-a-new-chairman-and-composition-of-spago-nanomedicals-board</guid>
<pubDate>Thu, 20 Mar 2025 07:20:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / March 20, 2025 /Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the company's nomination committee proposes a changed board composition to meet the needs of the company's current ...</description>
</item>
<item>
<title>Spago Nanomedical Proceeds with Increased Dose in the Phase I/IIa study Tumorad-01</title>
<link>https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-proceeds-with-increased-dose-in-the-phase-iiia-study-tumorad-01</link>
<guid isPermaLink="true">https://6ix.com/company/spago-nanomedical-ab/news/spago-nanomedical-proceeds-with-increased-dose-in-the-phase-iiia-study-tumorad-01</guid>
<pubDate>Tue, 04 Mar 2025 07:15:00 GMT</pubDate>
<description>LUND, SE / ACCESSWIRE / March 04, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) recommends a dose increase in the ongoing phase I/IIa study Tumorad-01 ...</description>
</item>
</channel>
</rss>